Title:Effect of Niosomal Encapsulation of Quercetin and Silymarin and their
Combination on Dimethylnitrosoamine-induced and Phenobarbital promoted
Hepatocellular Carcinoma in Rat Model
Volume: 21
Issue: 5
Author(s): Devendra S. Shirode, Dinesh J. Raut and Nikita Sarasawat*
Affiliation:
- Department of Pharmacology, Dr. D. Y. Patil College of Pharmacy Akurdi, Pune 411044, Maharashtra, India
Keywords:
Alpha-fetoprotein, bioavailability, DEN-induced model, hepatocellular carcinoma, hepatoprotective effects, silymarin, quercetin.
Abstract:
Background: Hepatocellular carcinoma is a particularly dangerous and severe kind of liver
cancer. Many anticancer drugs fail to complete the treatment of hepatocellular carcinoma without
any side effects. There should be appropriate and without side effective treatments for hepatocellular
carcinoma.
Objective: The objective of the current study was to evaluate how quercetin and silymarin in a niosomal
formulation affected hepatocyte carcinoma caused by diethylnitrosamine.
Methods: Five groups were created from the thirty male rats. Normal control (untreated group), tumor
group (administered dimethylnitrosoamine 200 mg/kg), treatment group I (administered 50 mg/kg of
niosomal encapsulated quercetin), treatment group II (administered 50 mg/kg of niosomal encapsulated
silymarin), and treatment group III (administered 50 mg/kg of niosomal encapsulated quercetin
+ silymarin). Then, biochemical estimation, serum analysis, and histopathological examination were
carried out.
Results: Treatment group III, treated with niosomal encapsulation of a combination of quercetin +
silymarin 50 mg/kg, demonstrated the significant restoration of alpha-fetoprotein and carcinoembryonic
antigen and also antioxidants like superoxide dismutase and nitric oxide. The histopathological
examination showed improved liver architecture in this group compared to other treatment groups.
Conclusion: Our findings revealed that a potent anticancer effect was observed in treatment group
III as niosomal formulation increased the bioavailability of the drug within the body. In order to
completely understand the underlying processes and evaluate the therapeutic effectiveness of these
chemicals in the therapy of hepatocellular carcinoma, further investigation and clinical trials are required.